PLoS ONE (Jan 2014)

Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients.

  • Paola Melotti,
  • Andrea Mafficini,
  • Patrick Lebecque,
  • Myriam Ortombina,
  • Teresinha Leal,
  • Emily Pintani,
  • Xavier Pepermans,
  • Claudio Sorio,
  • Baroukh Maurice Assael

DOI
https://doi.org/10.1371/journal.pone.0114274
Journal volume & issue
Vol. 9, no. 12
p. e114274

Abstract

Read online

Macrophage migration Inhibitory Factor (MIF) is a pro-inflammatory cytokine sustaining the acute response to gram-negative bacteria and a regulatory role for MIF in Cystic Fibrosis has been suggested by the presence of a functional, polymorphic, four-nucleotide repeat in this gene's promoter at position -794, with the 5-repeat allele displaying lower promoter activity. We aimed at assessing the association of this polymorphism with disease severity in a group of Cystic Fibrosis patients homozygous for F508del CFTR gene mutation. Genotype frequencies were determined in 189 Cystic Fibrosis and 134 control subjects; key clinical features of patients were recorded and compared among homozygous 5-allele patients and the other MIF genotypes. Patients homozygous for the 5-repeat allele of MIF promoter displayed a slower rate of lung function decline (p = 0.027) at multivariate survival analysis. Multiple regression analysis on age-normalized respiratory volume showed no association of the homozygous 5-repeat genotype with lung function under stable conditions and no correlation with P.aeruginosa chronic colonization. Therefore, only the Homozygous 5-repeat genotype at MIF -794 is associated with milder disease in F508del Cystic Fibrosis patients.